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Introduction
Xenobiotic-metabolizing P450 enzymes act on chemically diverse small molecules, often with overlapping specificities, but with the formation of distinct metabolites and/or metabolic rates. The only active human cytochromes P450 in the 2A subfamily are CYP2A13 and CYP2A6. CYP2A13 is primarily expressed throughout the respiratory system including nasal mucosa, trachea, and lung (Su et al., 2000b; Zhu et al., 2006) , while CYP2A6 is primarily a hepatic enzyme (Yamano et al., 1990; Fernandez-Salguero et al., 1995) . Coumarin 7-hydroxylation is a characteristic activity for the P450 2A subfamily. However, reports disagree on whether the catalytic efficiency for coumarin is 10-fold higher for CYP2A6 compared to CYP2A13 (He et al., 2004b) or similar (von Weymarn and Murphy, 2003) . A number of other substrates are metabolized very differently by these two enzymes, including nicotine and the nicotine-derived compounds cotinine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). CYP2A13 metabolizes nicotine and cotinine with 23-and 15-fold higher catalytic efficiency (k cat /K m ) than CYP2A6, respectively (Bao et al., 2005) . Additionally, the metabolism of NNK by CYP2A13 occurs at a catalytic efficiency 215-fold greater than CYP2A6 (He et al., 2004a) . Both CYP2A13 and CYP2A6 have been implicated in tobacco-related lung cancers and have genetic polymorphisms reported to decrease cancer risk (Tan et al., 2001; Wang et al., 2003) .
CYP2A13 also functions in the activation of several other procarcinogens or the metabolism of toxins. Aflatoxin B 1 is efficiently activated by CYP2A13 to a mutagenic epoxide, an activity similar to CYP1A2, but is not activated by CYP2A6 . Phenacetin, an antipyretic drug used for many years and later found to be a kidney toxin, is O-deethylated DMD #26765 efficiently by both CYP1A2 and CYP2A13 (k cat /K m 0.36 for both enzymes), but not by CYP2A6 (Fukami et al., 2007; DeVore et al., 2008) .
Diversity in the functions of CYP2A13 and CYP2A6 is not likely to originate with the global structure as the enzymes are 94% identical, differing by only 32 amino acids and the crystallographically-determined structures have an overall root mean square deviation for the Cα carbons of only 0.5 Å (Smith et al., 2007) . Ten of the 32 amino acid differences are in or near the active site and are likely to be directly related to the functional differences observed in substrate metabolism. We have previously established that differential binding and metabolism of the analgesic phenacetin in human CYP2A enzymes is the result of the disparate amino acids at positions 208, 300, 301, and 369 in concert with the effects of those four substitutions on adjacent conserved residues Phe209 and Leu370 (DeVore et al., 2008) . The net steric effects of these differences alter active site morphology to determine CYP2A compatibility with phenacetin binding and O-deethylation. Other studies of human CYP2A enzymes have revealed that residues 117 and 372 are critical for both coumarin (He et al., 2004b) and NNK metabolism, and that the residue at position 208 is also critical for NNK metabolism (He et al., 2004a) .
The goal of the present work is to determine if these same amino acids are responsible for differential binding of other ligands by human CYP2A enzymes. In several cases, other P450 proteins are known to adapt to different ligands in a more induced-fit mode of binding, frustrating attempts at prediction of drug binding and metabolism. If the relatively small CYP2A selectivity is based on a more steric-dominated, lock-and-key type model, then xenobiotic binding to these enzymes may be suitably evaluated using docking methodologies based on the known crystal structures. In this study, we have surveyed a series of five structurally diverse cytochrome P450 2A ligands, nicotine, phenethyl isothiocyanate (PEITC), coumarin, 2'-DMD #26765 6 methoxyacetophenone (MAP), and 8-methoxypsoralen (MOP). Coumarin, PEITC, and MAP were identified to have a range of differential affinities for the human CYP2A enzymes and were thus used to investigate the effects of mutations at ten active site positions differing between CYP2A6 and CYP2A13. These ligand binding studies identified a number of substitutions that changed the K D significantly for at least one substrate. Substitutions combining three or four of these CYP2A13 amino acid residues into CYP2A6 indicate that the differences between CYP2A13 and CYP2A6 binding affinities observed for the ligands in this study are largely dependent on the same four residues identified in the phenacetin study : 208, 300, 301, and 369 (DeVore et al., 2008) . In order to evaluate the roles that individual features of the active site have in modulating ligand binding affinity, we performed structure-based quantitative structureactivity relationship (QSAR) analysis via the COMBINE method, whose results were consistent with a steric binding rationale.
This article has not been copyedited and formatted. The final version may differ from this version. 
Protein expression and purification:
The human CYP2A13 and CYP2A6 proteins used in these studies were all generated by deleting the N-terminal transmembrane sequence (Δ2-23), altering several residues at the modified N-terminus (from 24-WRQRKSR-30 to 24-AKKTSSK-30) and adding four histidine residues at the C-terminus. All mutations were also made in this background. Many studies with several different membrane P450 enzymes have shown that truncated versions metabolize the same substrates as the full-length parent enzyme with the same regio-and stereoselectivity (von Wachenfeldt et al., 1997; Scott et al., 2001; Schoch et al., 2004; Wester et al., 2004) . Given substantial differences in the availability and purity of full-length and truncated enzymes and differences in the requirement for lipid, direct comparisons of activity rates are difficult, but similar activities and binding have been reported Yano et al., 2004) . Use of the truncated versions allow a far greater yield of protein than could be attained with the full-length enzyme (Scott et al., 2001) . These modifications allow generation of highly purified protein that retains its catalytic activity and in quantities that are sufficient for ligand binding and other biophysical studies. Such truncated CYP2A proteins were expressed with yields ranging from 320 -1100 nmol/liter of culture at the microsome stage and further purified as described (Smith et al., 2007) . The total yield of purified protein ranged from 17.4-155 nmol P450/liter of E. coli culture. Two mutant proteins, CYP2A6 I208S/I300F/G301A and CYP2A6 I208S/I300F/G301A/S369G had specific contents of >3-3.5 nmol/mg, but all other This article has not been copyedited and formatted. The final version may differ from this version. proteins had specific contents ranging from 10.4 -19.3 nmol/mg. These CYP2A proteins were competent in the metabolism of phenacetin as previously reported (DeVore et al., 2008) .
Site-directed mutagenesis:
The mutations were generated using the modified CYP2A gene in an expression vector (pKK2A13dH) or (pKK2A6dH) as a template (13) and the Quikchange® Site-Directed Mutagenesis method (Stratagene, La Jolla, CA). Synthetic oligonucleotides were designed to yield the desired amino acid substitution, but also to contain silent restriction site mutations where possible to facilitate identification of mutated genes (Table   1 ). Oligonucleotides were synthesized by Genosys (Woodlands, TX).
Ligand binding titrations:
Binding titrations with the ligands were conducted with purified P450 protein at 20°C using a UV-2101 UV-visible scanning spectrophotometer (Shimadzu Scientific Instruments, Inc., Columbia, MD). Protein was diluted to 1 μM in 100 mM potassium phosphate buffer, pH 7.4. Diluted protein was equally divided between two 1.0 ml quartz cuvettes (1-cm path length), and a baseline was recorded (300 to 500 nm). Freshly prepared aliquots of ligand dissolved in 100% ethanol were added to the sample cuvette. An equal volume of ethanol was added to the reference cuvette. Difference spectra were collected (300 to 500 nm) after an equilibration period. During the spectral titrations, the total amount of ethanol added did not exceed 2%. Binding to P450 was monitored as the absorbance difference (ΔA) between the minimum (~420 nm) and the maximum (~385 nm). The apparent binding constant (K D ) and the maximum spectral change (ΔA max ) were determined from nonlinear least-squares regression fitting to the following equation: (Ortiz et al., 1995) . Protein structures were generated from crystal structures of human CYP2A13 with indole bound (2P85; (Smith et al., 2007) ) and human CYP2A6 complexed with methoxsalen (PDB code 1Z11; (Yano et al., 2005) ). Mutations of CYP2A13 were performed in silico via the Biopolymer suite in Insight-II (Accelrys, San Diego, CA) and each unique mutant protein was allowed to relax via CHARMM simulations (Brooks et al., 1983 ) entailing a 100 step molecular mechanics preconditioning run to alleviate clashes induced by the point mutation, a 20 ps molecular dynamics (MD) warmup, a 20 ps thermal equilibration and a 100 ps analysis run. In all cases, the native ligand (i.e., indole and methoxsalen for CYP2A13 and CYP2A6 respectively) and crystallographic waters were retained throughout the simulation. All atomic charge and force field parameters corresponded to standard CHARMM terms (Brooks et al., 1983) . For each unique protein, the conformation present at the end of the analysis run was used for ligand docking and subsequent COMBINE analysis.
In order to derive a bound conformer for coumarin bound to CYP2A6, the known crystal structure of this complex (PDB code 1Z10 (Yano et al., 2005) ) was aligned to the relaxed , 1996) . In each case the protein structure was stripped of the native ligand and all waters except the one closest to the Asn297 side chain (due to observations in the CYP2A13 crystal structure that it served to bridge between indole and the Asn 297 side chain). Fifty poses were then requested per ligand, using default charge and conformational search setting. For mutant protein CYP2A13 A117V, docking simulations for the ligands MAP and coumarin did not achieve a reasonable bound structure, thus the initial guess positions of these two ligands were derived by aligning to the conformations attained for the CYP2A13 protein.
The set of COMBINE descriptors employed for QSAR analysis constituted of van der Waals (vdW) and electrostatics interaction terms between each ligand and each residue (i.e., including all amino acids, plus the heme and the one water) present in each of the 12 proteins.
The QSAR model was then trained by partial least squares fitting as implemented in the Simca P 
Results
Binding of structurally diverse ligands to CYP2A6 and CYP2A13 proteins:
Initially a series of five structurally diverse cytochrome P450 2A ligands were surveyed and binding affinities determined for both CYP2A6 and CYP2A13 enzymes. Coumarin was chosen because it is an often-used marker substrate for cytochromes P450 in the 2A subfamily (FernandezSalguero et al., 1995; He et al., 2004b; Kim et al., 2005) . Nicotine (Bao et al., 2005; Murphy et al., 2005) and 2'-methoxyacetophenone (MAP) (Su et al., 2000a; von Weymarn et al., 2005) All five of the ligands surveyed bound more tightly to CYP2A13 than to CYP2A6 (Table   2 ), but with a substantial range in both overall affinities and in the differences in affinity between the two enzymes. The ligand that bound the tightest to both enzymes is 8-methoxypsoralen. In contrast, nicotine had the lowest affinity for both enzymes. MAP, PEITC, and coumarin had
In terms of differential affinities, the compounds fall into three groups. First, coumarin binds equally well to both enzymes. Second, nicotine, 8-MOP, and PEITC have moderate selectivity for CYP2A13. The substrate nicotine binds to CYP2A13 4.7 times more tightly than to CYP2A6, while the inhibitors PEITC and MOP bind to CYP2A13 13-to 14-fold more tightly than to CYP2A6. The ligand with the largest difference in binding affinity is MAP, which binds 74-fold more tightly to CYP2A13 than to CYP2A6.
This article has not been copyedited and formatted. The final version may differ from this version. Ligand binding to mutants of CYP2A13: Of the five ligands surveyed above, MAP, PEITC, and coumarin were chosen to characterize mutant CYP2A proteins in which active site amino acids from the opposite CYP2A enzyme were substituted. These three ligands were chosen because they span the range of differences observed in K D values, from MAP with its 74-fold differences in binding affinity, to PEITC with a moderate 14-fold difference in affinity, to coumarin which binds equally well to both proteins. The ten amino acids that were mutated were selected based on their location within the CYP2A6 and CYP2A13 active sites ( Figure 2) and their effects on phenacetin binding and metabolism (DeVore et al., 2008 In contrast to PEITC and MAP, which bind more tightly to CYP2A13 than CYP2A6, the K D value for coumarin is ~2.9 µM for both CYP2A13 and CYP2A6. Again, the F300I substitution had the most dramatic effect on K D , with a 5-fold increase. Two other substitutions, G369S and S208I, increased K D values by 2-and 3-fold, respectively. The substitution H372R increased coumarin binding affinity by nearly 50% to a K D of 1.5 µM, while L366I increased coumarin binding affinity by 5-fold to 0.57 µM.
Ligand Binding to CYP2A6 Multiple Mutants:
The above studies revealed amino acids that decreased CYP2A13 affinity for MAP and PEITC (Figure 3 ), but it is much easier to disrupt ligand binding than to improve it. To verify that these same amino acids would increase CYP2A6 binding affinity for MAP and PEITC, several of these substitutions were incorporated into CYP2A6 and binding of the same three ligands was evaluated. Since mutations at 208, 300, and 301 had the largest negative effects on MAP and PEITC affinity for CYP2A13, the CYP2A6 triple mutant I208S/I300F/G301A was generated. This mutated protein had affinities for MAP and PEITC that were intermediate between CYP2A6 and CYP2A13 (Table 3) the case of A301G, however, this is universally not the case. However, the modeling results suggest that while the alanine to glycine mutation itself opens up space in the active site closer to the polar end of the ligands, there is a slight shift of the I helix backbone and Phe300 toward the ligand that actually leads to slightly greater constriction in the area of the lipophilic group ( Figure 5B) . Comparison of the aligned CYP2A6 and CYP2A13 experimentally determined crystal structures, reveals a slight helical kinking that arises in the proximity of residue 301 that occludes the cavity by about ~0.2 Å in the case of CYP2A6.
Finally, conserved amino acids Asn297, Leu370, and Phe480 also have significant steric roles in this model. Asn297, which is considered to be the lone available H-bonding site in the CYP2A active sites, has the second largest contribution for an amino acid. The one favorable protein steric contribution to ligand binding in the COMBINE model is the conserved amino acid Leu370, which is located near ligand hydrophobic groups. In this case, the best interpretation of its status as a favorable contact is that mild steric clashes with ligands are compensated for with favorable entropy, desolvation energy, or some combination of the two. The benefits of desolvation are obvious in that in all complexes the ligand places a hydrophobic group in the vicinity of Leu370's hydrophobic side chain. Entropy is also a plausible contributor in that Leu370 is easily the most mobile side chain observed in the COMBINE modeling studies. The extent of this variability in this side chain in our modeling studies is evident in Figure 5C , wherein the Leu370 side chain location and conformation is depicted for a series of relevant proteins. Leu370 is also located between Leu366 and His372. Explaining of the effects of mutations of these two residues (CYP2A13 L366I and H372R) with MAP and coumarin constitute the greatest shortcoming of the COMBINE model. Coumarin binds to CYP2A6 by hydrogen bonding with Asn297, adopting an orientation within a largely planar active site that positions C7 for hydroxylation (Yano et al., 2005) , consistent with the only coumarin metabolite detected for CYP2A6. Asn297 and the planar active site are conserved in CYP2A13 (13), as is the generation of 7-hydroxycoumarin.
Consistent with these similarities, the nearly identical K D values for both proteins suggest that coumarin binds similarly in CYP2A13. However, CYP2A13 also forms a significant amount of 3,4 epoxide and smaller amounts of 6-hydroxy-and 8-hydroxycoumarin (von Weymarn and Murphy, 2003) . This suggests that CYP2A13 binds coumarin via N297 hydrogen bonding, but is less constrained in its approach to the activated oxygen on the heme so that C6 or C8 can also be hydroxylated and also binds coumarin in a second, inverted orientation to expose C3/C4 for epoxidation.
MAP is O-demethylated by both enzymes to produce 2'-hydroxyacetophenone and formaldehyde, and its binding showed the largest difference in affinity among the ligands examined. Although kinetics are not available for MAP metabolism, Su et al. reported that at 1 mM substrate concentration, CYP2A13 metabolized MAP at a rate 4-fold faster than CYP2A6 (Su et al., 2000a) . Thus, the scale of the differences in MAP affinity were unexpected based on the single productive orientation in the active site suggested by a single product and the preliminary metabolic rate information available. structures reveal that I300 and F300 overlap at the alpha carbon atom, but that the phenyl ring is torsioned farther away from the bound ligand than the isoleucine side chain in both CYP2A13
and the CYP2A6 quadruple mutant (Yano et al., 2005; Smith et al., 2007; DeVore et al., 2008) .
The amino acid at this position is key for phenacetin (DeVore et al., 2008) and indole metabolism in CYP2A enzymes. Overall, it is clear that this residue is critical for the higher affinity of CYP2A13 for PEITC and MAP, playing a key role in substrate selectivity.
This article has not been copyedited and formatted. The final version may differ from this version. Substitution of the adjacent CYP2A13 residue, A301, to glycine removes the side chain and causes 7-to 8-fold increases in the K D for MAP and PEITC, respectively, but does not significantly alter the K D for coumarin. This suggests that coumarin interacts differently with the residue at position 300 than does MAP or PEITC. Since MAP and PEITC bind more tightly to CYP2A13, interactions with this residue also contribute to ligand selectivity.
The S208I substitution has a 14-fold increase in the K D for MAP, but much smaller ~3-fold effects on PEITC and coumarin binding. Since MAP is the ligand with the most contrast in affinity between the two CYP 2A enzymes, interactions with this residue may also be significant in ligand selectivity. The more moderate effects on coumarin binding are consistent with the results of He et al., which showed that this mutation had little effect on the kinetics of coumarin 7-hydroxylation by CYP2A13 (He et al., 2004b) . This mutation is also reported to decrease the catalytic efficiency of CYP2A13 NNK metabolism to both the keto aldehyde and keto alcohol products, neither of which are formed efficiently by CYP2A6 (He et al., 2004a) .
COMBINE evaluation of the influence of electrostatics revealed that the extended heme system is found to exert the dominant influence, favoring ligands that orient negatively charged groups toward the positively charged iron. The key non-heme electrostatic interaction is predicted to be with a water molecule that was isolated as an apparent H-bond donor in the CYP2A13/indole crystal structure (Smith et al., 2007) and may help to bridge the ligand with the conserved Asn297 donor site, but whose position was not rigorously conserved during molecular dynamics relaxation of all mutants. Thus no significant electrostatic differences were identified between CYP2A6 and CYP2A13 that are likely to directly affect ligand binding. In contrast, the COMBINE model identified several differing amino acids at positions 300, 301, and 117 that do have important steric contributions. All three residues have substantial effects on not only the incorporated into CYP2A6, resulting in an enzyme whose overall binding affinities for all three ligands were much more similar to CYP2A13.
In conclusion, the goal of this study was to gain insight into the differences in structure- 
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